Michael P O'Leary1, Brian J Beckord1, Kyle E Mock1, Rose J Venegas2, James J Yeh3, Christine E Dauphine1, Junko J Ozao-Choy1. 1. Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA. 2. Department of Pathology, Division of Cytopathology, Harbor UCLA Medical Center, Torrance, CA, USA. 3. Department of Medicine, Division of Medical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA.
Abstract
BACKGROUND: Pertuzumab has improved pathologic complete response rates when compared with other chemotherapeutics in the treatment of HER-2 positive breast cancer patients. AIMS: We sought to determine if axillary lymph node dissections (ALNDs) yielding at least the national standard of 10 lymph nodes is lower in patients who received neoadjuvant pertuzumab. METHODS AND RESULTS: A retrospective database identified patients who underwent ALND for breast cancer. We compared the axillary lymph node retrieval rates in those who received or did not receive neoadjuvant pertuzumab. Of 139 breast cancer patients who underwent ALND, fewer than 10 axillary lymph nodes were found in 41.7% of patients who received neoadjuvant pertuzumab (P < 0.01) and 18.6% of patients who received neoadjuvant therapy without pertuzumab (P = 0.01). CONCLUSION: Neoadjuvant chemotherapy was associated with a significantly lower rate of "adequate" ALNDs as defined by current guidelines. The patient subset that received neoadjuvant pertuzumab was more likely to have fewer than 10 axillary lymph nodes retrieved.
BACKGROUND:Pertuzumab has improved pathologic complete response rates when compared with other chemotherapeutics in the treatment of HER-2 positive breast cancerpatients. AIMS: We sought to determine if axillary lymph node dissections (ALNDs) yielding at least the national standard of 10 lymph nodes is lower in patients who received neoadjuvant pertuzumab. METHODS AND RESULTS: A retrospective database identified patients who underwent ALND for breast cancer. We compared the axillary lymph node retrieval rates in those who received or did not receive neoadjuvant pertuzumab. Of 139 breast cancerpatients who underwent ALND, fewer than 10 axillary lymph nodes were found in 41.7% of patients who received neoadjuvant pertuzumab (P < 0.01) and 18.6% of patients who received neoadjuvant therapy without pertuzumab (P = 0.01). CONCLUSION: Neoadjuvant chemotherapy was associated with a significantly lower rate of "adequate" ALNDs as defined by current guidelines. The patient subset that received neoadjuvant pertuzumab was more likely to have fewer than 10 axillary lymph nodes retrieved.
Authors: Heather Neuman; Lisa A Carey; David W Ollila; Chad Livasy; Benjamin F Calvo; Anthony A Meyer; Hong Jin Kim; Michael O Meyers; E Claire Dees; Fran A Collichio; Carolyn I Sartor; Dominic T Moore; Lynda R Sawyer; Jill Frank; Nancy Klauber-DeMore Journal: Am J Surg Date: 2006-06 Impact factor: 2.565
Authors: Michael P O'Leary; Brian J Beckord; Kyle E Mock; Rose J Venegas; James J Yeh; Christine E Dauphine; Junko J Ozao-Choy Journal: Cancer Rep (Hoboken) Date: 2018-09-16
Authors: H M Kuerer; A A Sahin; K K Hunt; L A Newman; T M Breslin; F C Ames; M I Ross; A U Buzdar; G N Hortobagyi; S E Singletary Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés Journal: Ann Oncol Date: 2013-05-22 Impact factor: 32.976
Authors: Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga Journal: Lancet Oncol Date: 2013-04-18 Impact factor: 41.316
Authors: Michael P O'Leary; Brian J Beckord; Kyle E Mock; Rose J Venegas; James J Yeh; Christine E Dauphine; Junko J Ozao-Choy Journal: Cancer Rep (Hoboken) Date: 2018-09-16